Case number 2017-2153
Horizon Pharma Ireland v. Actavis Laboratories UT, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 3, 2020 | 25 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [675872] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 03/03/2020 01:50 PM] (1) |
| Oct 10, 2019 | 23 | OPINION filed for the court by Prost, Chief Judge; Newman, Circuit Judge and Reyna, Circuit Judge. Opinion concurring in part and dissenting in part filed by Circuit Judge Newman. Precedential Opinion. [641453] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 10/10/2019 09:50 AM] (55) |
| Oct 10, 2019 | 24 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [641454] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [JAB] [Entered: 10/10/2019 09:51 AM] (2) |
| Jul 19, 2017 | 22 | ORDER granting motion to consolidate appeals [446747-2] filed by Cross-Appellant Actavis Laboratories UT, Inc. and Appellants Horizon Pharma USA, Inc., Horizon Pharma Ireland Limited and HZNP Limited in 17-2149; Appellants’ opening brief is due no later than August 14, 2017. All remaining deadlines are to be calculated in accordance with Federal Circuit Rule 31(a). Service: 07/19/2017 by clerk. [447715] [17-2149, 17-2152, 17-2153, 17-2202, 17-2203, 17-2206] [NL] [Entered: 07/19/2017 03:40 PM] (2) |
| Jun 30, 2017 | 17 | Amended Certificate of Interest for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/30/2017 by email. [443442] [Caryn Borg-Breen] [Entered: 06/30/2017 12:19 PM] (4) |
| Jun 30, 2017 | 18 | Corrected Entry of appearance for Caryn C. Borg-Breen as principal counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/30/2017 by email. [443510] [Caryn Borg-Breen] [Entered: 06/30/2017 01:54 PM] (2) |
| Jun 30, 2017 | 19 | Corrected Entry of appearance for Robert F. Green as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/30/2017 by email. [443514] [Caryn Borg-Breen] [Entered: 06/30/2017 01:54 PM] (2) |
| Jun 30, 2017 | 20 | Corrected Entry of appearance for Jessica M. Tyrus as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/30/2017 by email. [443515] [Caryn Borg-Breen] [Entered: 06/30/2017 01:55 PM] (2) |
| Jun 30, 2017 | 21 | Corrected Docketing Statement for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/30/2017 by email. [443517] [Caryn Borg-Breen] [Entered: 06/30/2017 01:57 PM] (4) |
| Jun 28, 2017 | 16 | Notice of Rejection to Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc., the following document(s) [7] certificate of interest. [8] docketing statement. [4] attorney entries of appearance , [5] [6] Reason(s) See order for additional details. [442891] [FMS] [Entered: 06/28/2017 03:13 PM] (1) |
| Jun 27, 2017 | 4 | Entry of appearance for Caryn C. Borg-Breen as principal counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442545] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:53 PM] (0) |
| Jun 27, 2017 | 5 | Entry of appearance for Robert F. Green as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442547] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:54 PM] (0) |
| Jun 27, 2017 | 6 | Entry of appearance for Jessica M. Tyrus as of counsel for Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442549] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:54 PM] (0) |
| Jun 27, 2017 | 7 | Certificate of Interest for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442550] This document has been rejected. See Doc No.[16] [Robert Green] [Entered: 06/27/2017 04:56 PM] (0) |
| Jun 27, 2017 | 8 | Docketing Statement for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc.. Service: 06/27/2017 by email. [442551] This document has been rejected. See Doc No. [16] [Robert Green] [Entered: 06/27/2017 04:57 PM] (0) |
| Jun 27, 2017 | 9 | Transcript Purchase Order Form for the Appellants HZNP Limited, Horizon Pharma Ireland Limited and Horizon Pharma USA, Inc. indicating that a transcript is already on file. Service: 06/27/2017 by email. [442552] [Robert Green] [Entered: 06/27/2017 04:57 PM] (2) |
| Jun 27, 2017 | 10 | Entry of appearance for John Christopher Rozendaal as principal counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442563] [John Rozendaal] [Entered: 06/27/2017 05:25 PM] (2) |
| Jun 27, 2017 | 11 | Certificate of Interest for the Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442564] [John Rozendaal] [Entered: 06/27/2017 05:26 PM] (3) |
| Jun 27, 2017 | 12 | Docketing Statement for the Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442565] [John Rozendaal] [Entered: 06/27/2017 05:27 PM] (4) |
| Jun 27, 2017 | 13 | Entry of appearance for Michael E. Joffre as of counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442568] [Michael Joffre] [Entered: 06/27/2017 05:32 PM] (2) |
| Jun 27, 2017 | 14 | Entry of appearance for Kristina Caggiano Kelly as of counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442572] [Kristina Caggiano Kelly] [Entered: 06/27/2017 05:36 PM] (2) |
| Jun 27, 2017 | 15 | Entry of appearance for William H. Milliken as of counsel for Cross-Appellant Actavis Laboratories UT, Inc.. Service: 06/27/2017 by email. [442577] [William Milliken] [Entered: 06/27/2017 05:40 PM] (2) |
| Jun 22, 2017 | 2 | Note to file: The following cases are associated:17-2153 Lead with 17-2203 Cross-Appeal. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [441387] [17-2153, 17-2203] [FMS] [Entered: 06/22/2017 01:00 PM] (0) |
| Jun 22, 2017 | 3 | Note to file: 17-2152 (COMPANION started 06/22/2017) with 17-2149 and 17-2153 (COMP COMPANION started 06/22/2017) with 17-2149. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [441445] [17-2149, 17-2152, 17-2153] [FMS] [Entered: 06/22/2017 03:00 PM] (0) |
| Jun 14, 2017 | 1 | Appeal docketed. Received: 06/12/2014. [439195]Entry of Appearance due 06/28/2017. Certificate of Interest is due on 06/28/2017. Docketing Statement due 06/28/2017. Appellant/Petitioner's brief is due 08/14/2017. [FMS] [Entered: 06/14/2017 12:50 PM] (19) |
